Bellicum Reports Second Quarter 2021 Financial Results and Provides Operational Update
12 août 2021 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
- Entered into a licensing agreement with two leading oncology research and treatment centers for use of CaspaCIDe® safety switch technology - - Enrollment continuing in Phase 1/2 dose-escalation...
Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update
17 mai 2021 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update
30 mars 2021 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
Enrolled first patient in Phase 1/2 clinical trial for BPX-603 in solid tumors that express HER2 Clinical hold lifted on Phase 1/2 dose-escalation trial evaluating BPX-601 and rimiducid in...
Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
23 mars 2021 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will...
Bellicum Announces First Reported Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity
04 mars 2021 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the...
Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial
28 janv. 2021 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the...
Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603
10 déc. 2020 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment...
Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial
07 déc. 2020 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has...
Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update
05 nov. 2020 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
Strategic focus on clinical GoCAR-T® programs with plans to initiate Phase 1/2 enrollment of BPX-601 in mCRPC and BPX-603 in HER2+ solid tumors by end of year Completed offering of shares of common...
Bellicum Pharmaceuticals Announces Closing of $25.0 Million Underwritten Offering
03 nov. 2020 20h26 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the closing...